NEI Research News

The team identified small molecules that can reduce the production of proteins linked to age-related macular degeneration.

Researchers from the National Institutes of Health (NIH) have discovered the source of dysfunction in the process whereby cells in the eye's retina remove waste.

Researchers have found that taking a daily supplement containing antioxidant vitamins and minerals slows progression of late-stage dry age-related macular degeneration (AMD), potentially helping people preserve their central vision.

A new study in mice hints at the promise of an eventual alternative treatment option for the “wet” version of age-related macular degeneration (AMD).

At a fraction of the cost, biosimilars are now proven to be as effective as original anti-VEGF medications.

A gene previously implicated in the development of atherosclerotic lesions in coronary arteries could be key to understanding why many people don’t benefit from the most used therapy for neovascular age-related macular degeneration (AMD).

Researchers at the National Institutes of Health applied artificial intelligence (AI) to a technique that produces high-resolution images of cells in the eye. They report that with AI, imaging is 100 times faster and improves image contrast 3.5-fold.

National Eye Institute researchers studying human retinas discovered 87 target genes where a mix of environmental factors likely influence one’s risk of developing age-related macular degeneration (AMD), a leading cause of vision loss.

The drug minocycline, an antibiotic that also decreases inflammation, failed to slow vision loss or expansion of geographic atrophy in people with dry age-related macular degeneration (AMD), according to a phase II clinical study.

The technique, known by the research team as a “monocyte factory,” makes possible a theoretically limitless source of human immune cells for research and the development of therapies for a variety of conditions including eye disease.